1.25

2.46% 0.03

After Hours: 1.23 -0.02 -1.60%

Opko Health Inc (OPK)

Overview News Price History Option Chain Financials Why OPK Down? Discussions Forecast

Opko Health Inc stock is traded at $1.25, with a volume of 1.57M. It is up +2.46% in the last 24 hours and down -8.09% over the past month. OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.

Previous Close:

$1.22

Open:

$1.24

24h Volume:

1.57M

Relative Volume:

0.48

Market Cap:

$959.63M

Revenue:

$711.41M

Net Income/Loss:

$-133.73M

P/E Ratio:

-6.5789

EPS:

-0.19

Net Cash Flow:

$-199.99M

1W Performance:

+0.00%

1M Performance:

-8.09%

6M Performance:

-3.85%

1Y Performance:

-22.84%

1-Day Range:

$1.22

$1.25

1-Week Range:

$1.21

$1.26

52-Week Range:

$1.11

$2.035

Opko Health Inc Stock (OPK) Company Profile

Name

Opko Health Inc

Sector

Healthcare (1108)

Industry

Diagnostics & Research (52)

Phone

305-575-4181

Address

4400 BISCAYNE BLVD., MIAMI, FL

Employee

2,997

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

OPK's Discussions on Twitter

Compare OPK vs TMO, DHR, IDXX, A, WAT

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OPK Opko Health Inc	1.25	936.60M	711.41M	-133.73M	-199.99M	-0.19
TMO Thermo Fisher Scientific Inc	527.17	202.81B	44.56B	6.73B	6.29B	17.74
DHR Danaher Corp	219.98	155.34B	24.57B	3.60B	5.25B	5.0475
IDXX Idexx Laboratories Inc	648.73	51.63B	4.30B	1.06B	1.04B	13.08
A Agilent Technologies Inc	128.90	36.49B	6.95B	1.30B	1.15B	4.5696
WAT Waters Corp	329.20	32.08B	3.11B	648.81M	602.27M	10.88

Opko Health Inc Stock (OPK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-20-25	Initiated	JP Morgan	Neutral
Oct-31-25	Downgrade	Jefferies	Buy → Hold
Apr-25-25	Initiated	JP Morgan	Neutral
Jun-29-23	Upgrade	Barrington Research	Mkt Perform → Outperform
Dec-15-22	Initiated	H.C. Wainwright	Buy
Jan-24-22	Downgrade	Barrington Research	Outperform → Mkt Perform
Jun-21-21	Initiated	Ladenburg Thalmann	Buy
Nov-25-19	Initiated	Piper Jaffray	Overweight
Mar-02-18	Downgrade	JP Morgan	Neutral → Underweight
Sep-14-17	Downgrade	JP Morgan	Overweight → Neutral
Jun-21-16	Reiterated	Standpoint Research	Buy
Jun-03-16	Initiated	Standpoint Research	Buy
Mar-31-16	Reiterated	Barrington Research	Outperform
Oct-16-15	Initiated	JP Morgan	Overweight
Sep-11-15	Downgrade	Jefferies	Buy → Hold
Mar-03-15	Downgrade	Oppenheimer	Outperform → Perform
May-12-14	Reiterated	Oppenheimer	Outperform
Mar-14-14	Initiated	Oppenheimer	Outperform
Nov-13-13	Reiterated	Ladenburg Thalmann	Buy
May-30-13	Reiterated	Ladenburg Thalmann	Buy
Oct-22-12	Initiated	Barrington Research	Outperform
Dec-01-11	Reiterated	Ladenburg Thalmann	Buy
Jul-14-11	Initiated	Ladenburg Thalmann	Buy

View All

Opko Health Inc Stock (OPK) Latest News

05:08 AM

OPKO Health Insider Ups Holding During Year - Yahoo Finance

05:08 AM

Feb 08, 2026

Swing Trade: What is OPKO Health Incs 5 year growth outlookWeekly Risk Report & Precise Entry and Exit Recommendations - baoquankhu1.vn

Feb 08, 2026

Feb 06, 2026

Opko Health (OPK) Expands Entera Partnership for Drug Co-Development - Insider Monkey

Feb 06, 2026

11 Best Stocks Under $3 to Buy Right Now - Insider Monkey

Feb 06, 2026

Feb 04, 2026

OPKO and Entera expand collaboration to develop oral PTH treatment By Investing.com - Investing.com Nigeria

Feb 04, 2026

Opko Health and Entera Bio expand partnership to advance first-in-class oral long acting PTH tablet for patients with hypoparathyroidism - marketscreener.com

Feb 04, 2026

OPKO and Entera expand collaboration to develop oral PTH treatment - Investing.com

Feb 04, 2026

Entera Bio Expands OPKO Partnership, Adds New Director - TipRanks

Feb 04, 2026

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism - The Manila Times

Feb 04, 2026

Opko Health And Entera Bio Expand Partnership To Advance First-In-Class Oral Long Acting Pth Tablet For Patients With Hypoparathyroidism - TradingView

Feb 04, 2026

OPKO Health and Entera Bio expand partnership for oral PTH tablet - StreetInsider

Feb 04, 2026

Entera Bio Signs Amended And Restated Collaboration And License Agreement With OPKO - TradingView

Feb 04, 2026

Entera Bio (NASDAQ: ENTX) widens OPKO partnership and appoints Steven Rubin to board - Stock Titan

Feb 04, 2026

OPKO Health and Entera Bio Expand Partnership to Advance - GlobeNewswire

Feb 04, 2026

Feb 02, 2026

Market Review: Is OPKO Health Inc likely to announce a buybackJuly 2025 Volume & Fast Entry High Yield Tips - baoquankhu1.vn

Feb 02, 2026

Jan 27, 2026

OPKO Health: Deeply Mispriced Ahead Of Major Catalysts (NASDAQ:OPK) - Seeking Alpha

Jan 27, 2026

Jan 26, 2026

EV Market: Will OPKO Health Inc benefit from seasonality2025 Major Catalysts & Precise Buy Zone Identification - baoquankhu1.vn

Jan 26, 2026

Analyst Calls: Does RAMP align with a passive investing strategyCPI Data & Low Risk Investment Opportunities - baoquankhu1.vn

Jan 26, 2026

OPKO Health, Inc. (NASDAQ:OPK) Receives Average Rating of "Hold" from Analysts - MarketBeat

Jan 26, 2026

Jan 24, 2026

OPKO Health (NASDAQ:OPK) Stock Passes Below 50 Day Moving AverageWhat's Next? - MarketBeat

Jan 24, 2026

Jan 22, 2026

Update Recap: What is OPKO Health Incs 5 year growth outlookJuly 2025 PostEarnings & Real-Time Chart Pattern Alerts - baoquankhu1.vn

Jan 22, 2026

Jan 21, 2026

Movement Recap: What drives Simulations Plus Incs stock priceQuarterly Trade Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn

Jan 21, 2026

Jan 20, 2026